Loading
Somatostatin receptor-positive means a neuroendocrine tumour takes up a DOTATATE tracer on PET. It is the requirement for lutetium-177 dotatate and the marker that predicts response to octreotide and lanreotide.
Gallium-68 or copper-64 DOTATATE PET (Netspot, Detectnet) images SSTR2; the Lutathera label covers somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, including foregut, midgut and hindgut, in adults and children 12 and over, with the NETTER-1 trial requiring uptake at least equal to liver (Krenning score 2 or higher) on every lesion. The Krenning scale (0 to 4, from no uptake to greater than spleen or kidney) is the historic scintigraphy score carried over to PET. Actinium-225 DOTATATE and other radioligands in trials use the same selection.
In plain words · Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care.
A DOTATATE PET scan that lights up your tumour at least as brightly as your liver makes it somatostatin receptor-positive, which is needed for lutetium-177 dotatate and predicts benefit from the monthly somatostatin injections. Tumours that do not take up the tracer, often the fast-growing ones, need a different plan.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
Tumour uptake of a somatostatin receptor PET tracer at least equal to normal liver (Krenning score 2 or higher) in target lesions; the Lutathera label states 'somatostatin receptor-positive' without a numeric cut-off.
“LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.”
Lutathera prescribing information| Threshold | Drug | Cancer | Regulator | Source |
|---|---|---|---|---|
| Somatostatin receptor-positive by SSTR imaging | Lutetium-177 dotatate | Neuroendocrine tumours | FDA | label |
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares Ki-67 index (proliferation by IHC) and the tag biomarker.
Shares Actinium-225 DOTATATE, Lutetium-177 dotatate, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
Shares Ki-67 index (proliferation by IHC) and the tag biomarker.
Shares Neuroendocrine tumour grade (Ki-67) and WHO classification, Ki-67 index (proliferation by IHC), Neuroendocrine tumours.
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Theranostics, Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Lutetium-177 dotatate, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares PSMA expression by PET (PSMA-positive) and the tag biomarker.